•
Dec 31, 2024

McKesson Q3 2025 Earnings Report

Expected Revenue:$96.1B
+23.3% YoY
Expected EPS:$8.6
+22.2% YoY

Key Takeaways

McKesson's third quarter revenues increased by 18% to $95.3 billion, driven by growth in the U.S. Pharmaceutical segment. Adjusted Earnings per Diluted Share increased by 4% to $8.03, and the company raised its full year Adjusted EPS guidance range to $32.55 to $32.95.

Consolidated revenues increased by 18% to $95.3 billion.

Earnings per diluted share increased to $6.95.

Adjusted Earnings per Diluted Share increased by 4% to $8.03.

McKesson raised and narrowed fiscal 2025 Adjusted Earnings per Diluted Share guidance to $32.55 to $32.95.

Total Revenue
$95.3B
Previous year: $80.9B
+17.8%
Gross Profit
$3.28B
Previous year: $3.15B
+4.2%
Cash and Equivalents
$1.13B
Previous year: $1.98B
-42.9%
Free Cash Flow
-$2.51B
Previous year: -$251M
+899.6%
Total Assets
$71.1B
Previous year: $66.5B
+6.9%

McKesson

McKesson

McKesson Revenue by Segment

Forward Guidance

McKesson is raising and narrowing fiscal 2025 Adjusted Earnings per Diluted Share guidance to $32.55 to $32.95 from the previous range of $32.40 to $33.00.